XML 101 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Additional Information (Details)
 12 Months Ended
Dec. 31, 2024
USD ($)
Segment
Segment Reporting Information [Line Items]  
Number of reportable segments | Segment 2
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Chief Executive Officer [Member]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.
Segment Reporting, Expense Information Used by CODM, Description These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.
Inter-segment  
Segment Reporting Information [Line Items]  
Revenue | $ $ 0